Charles Stoecker1, Lindsay Kim2, Ryan Gierke2, Tamara Pilishvili2. 1. Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, 1440 Canal St #8346, New Orleans, LA, 70112, USA. cfstoecker@tulane.edu. 2. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: Recently released results from a randomized controlled trial have shown that 13-valent pneumococcal conjugate vaccine (PCV13) is efficacious against vaccine-type nonbacteremic pneumonia in adults. OBJECTIVE: We examined the incremental cost-effectiveness of adding PCV13 to the Advisory Committee on Immunization Practices (ACIP) adult immunization schedule. METHODS: We used a probabilistic model following cohorts of 50-, 60-, or 65-year-olds. We used separate vaccination coverage and disease incidence data for healthy and high-risk adults. Incremental cost-effectiveness ratios were determined for each potential vaccination strategy. RESULTS: In the base case scenario, our model indicated that adding PCV13 at age 65 or replacing 23-valent pneumococcal polysaccharide vaccine (PPSV23) at age 65 with PCV13 provided more value for money than adding PCV13 at ages 50 or 60. After projections of six additional years of herd protection from the childhood immunization program were incorporated, we found adding PCV13 dominated replacing PPSV23. For a cohort of 65-year-olds in 2013, the cost of adding PCV13 at age 65 to the schedule was $62,065 per quality-adjusted life year (QALY) gained, which rose to $272,621 after 6 years of projected herd protection. CONCLUSION: The addition of one dose of PCV13 for adults appears to have a cost-effectiveness ratio comparable to other vaccination interventions in the short run, though anticipated herd protection from the childhood immunization program may dramatically increase the cost per QALY after only a few years.
BACKGROUND: Recently released results from a randomized controlled trial have shown that 13-valent pneumococcal conjugate vaccine (PCV13) is efficacious against vaccine-type nonbacteremic pneumonia in adults. OBJECTIVE: We examined the incremental cost-effectiveness of adding PCV13 to the Advisory Committee on Immunization Practices (ACIP) adult immunization schedule. METHODS: We used a probabilistic model following cohorts of 50-, 60-, or 65-year-olds. We used separate vaccination coverage and disease incidence data for healthy and high-risk adults. Incremental cost-effectiveness ratios were determined for each potential vaccination strategy. RESULTS: In the base case scenario, our model indicated that adding PCV13 at age 65 or replacing 23-valent pneumococcalpolysaccharide vaccine (PPSV23) at age 65 with PCV13 provided more value for money than adding PCV13 at ages 50 or 60. After projections of six additional years of herd protection from the childhood immunization program were incorporated, we found adding PCV13 dominated replacing PPSV23. For a cohort of 65-year-olds in 2013, the cost of adding PCV13 at age 65 to the schedule was $62,065 per quality-adjusted life year (QALY) gained, which rose to $272,621 after 6 years of projected herd protection. CONCLUSION: The addition of one dose of PCV13 for adults appears to have a cost-effectiveness ratio comparable to other vaccination interventions in the short run, though anticipated herd protection from the childhood immunization program may dramatically increase the cost per QALY after only a few years.
Authors: Cindy Parks Thomas; Marian Ryan; John D Chapman; William B Stason; Christopher P Tompkins; Jose A Suaya; Daniel Polsky; David M Mannino; Donald S Shepard Journal: Chest Date: 2012-10 Impact factor: 9.410
Authors: Lone Simonsen; Robert J Taylor; Cynthia Schuck-Paim; Roger Lustig; Michael Haber; Keith P Klugman Journal: Lancet Respir Med Date: 2014-03-10 Impact factor: 30.700
Authors: Lisa A Jackson; Alejandra Gurtman; Kathryn Rice; Karlis Pauksens; Richard N Greenberg; Thomas R Jones; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma Journal: Vaccine Date: 2013-05-18 Impact factor: 3.641
Authors: Marie R Griffin; Yuwei Zhu; Matthew R Moore; Cynthia G Whitney; Carlos G Grijalva Journal: N Engl J Med Date: 2013-07-11 Impact factor: 91.245
Authors: Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith Journal: Am J Prev Med Date: 2020-01-28 Impact factor: 5.043
Authors: Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith Journal: Vaccine Date: 2019-03-04 Impact factor: 3.641
Authors: Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith Journal: J Community Health Date: 2020-02
Authors: Angela R Wateska; Mary Patricia Nowalk; Chyongchiou J Lin; Lee H Harrison; William Schaffner; Richard K Zimmerman; Kenneth J Smith Journal: J Am Geriatr Soc Date: 2020-02-22 Impact factor: 5.562